264 related articles for article (PubMed ID: 27888143)
41. Preparation of budesonide- and indomethacin-hydroxypropyl-beta-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process.
Bandi N; Wei W; Roberts CB; Kotra LP; Kompella UB
Eur J Pharm Sci; 2004 Oct; 23(2):159-68. PubMed ID: 15451004
[TBL] [Abstract][Full Text] [Related]
42. In situ co-amorphisation of arginine with indomethacin or furosemide during immersion in an acidic medium - A proof of concept study.
Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
Eur J Pharm Biopharm; 2018 Dec; 133():151-160. PubMed ID: 30339888
[TBL] [Abstract][Full Text] [Related]
43. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
[TBL] [Abstract][Full Text] [Related]
44. Understanding the behavior of amorphous pharmaceutical systems during dissolution.
Alonzo DE; Zhang GG; Zhou D; Gao Y; Taylor LS
Pharm Res; 2010 Apr; 27(4):608-18. PubMed ID: 20151181
[TBL] [Abstract][Full Text] [Related]
45. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054
[TBL] [Abstract][Full Text] [Related]
46. Non-salt based co-amorphous formulation produced by freeze-drying.
Suleiman Alsalhi M; Royall PG; Al-Obaidi H; Alsalhi A; Cilibrizzi A; Chan KLA
Int J Pharm; 2023 Oct; 645():123404. PubMed ID: 37714312
[TBL] [Abstract][Full Text] [Related]
47. Influence of pH and method of crystallization on the solid physical form of indomethacin.
Dubbini A; Censi R; Martena V; Hoti E; Ricciutelli M; Malaj L; Di Martino P
Int J Pharm; 2014 Oct; 473(1-2):536-44. PubMed ID: 25064728
[TBL] [Abstract][Full Text] [Related]
48. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
Dhumal RS; Shimpi SL; Paradkar AR
Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
[TBL] [Abstract][Full Text] [Related]
49. Influence of Co-amorphization on the Physical Stability and Dissolution Performance of an Anthelmintic Drug Flubendazole.
Vasilev NA; Voronin AP; Surov AO; Perlovich GL
Mol Pharm; 2023 Mar; 20(3):1657-1669. PubMed ID: 36732935
[TBL] [Abstract][Full Text] [Related]
50. The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer.
Sormunen H; Ruponen M; Laitinen R
Int J Pharm; 2019 Oct; 570():118653. PubMed ID: 31472218
[TBL] [Abstract][Full Text] [Related]
51. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
Ruponen M; Visti M; Ojarinta R; Laitinen R
Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
[TBL] [Abstract][Full Text] [Related]
52. Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil.
Wlodarski K; Sawicki W; Haber K; Knapik J; Wojnarowska Z; Paluch M; Lepek P; Hawelek L; Tajber L
Eur J Pharm Biopharm; 2015 Aug; 94():106-15. PubMed ID: 25998701
[TBL] [Abstract][Full Text] [Related]
53. Solventless amorphization and pelletization using a high shear granulator. Part II; Preparation of co-amorphous mixture-layered pellets using indomethacin and arginine.
Kondo K; Rades T
Eur J Pharm Biopharm; 2022 Dec; 181():183-194. PubMed ID: 36400253
[TBL] [Abstract][Full Text] [Related]
54. Potential application of low molecular weight excipients for amorphization and dissolution enhancement of carvedilol.
Pešić N; Dapčević A; Ivković B; Kachrimanis K; Mitrić M; Ibrić S; Medarević D
Int J Pharm; 2021 Oct; 608():121033. PubMed ID: 34419592
[TBL] [Abstract][Full Text] [Related]
55. Enhancement of the physical stability of amorphous indomethacin by mixing it with octaacetylmaltose. inter and intra molecular studies.
Kaminska E; Adrjanowicz K; Zakowiecki D; Milanowski B; Tarnacka M; Hawelek L; Dulski M; Pilch J; Smolka W; Kaczmarczyk-Sedlak I; Kaminski K
Pharm Res; 2014 Oct; 31(10):2887-903. PubMed ID: 24831310
[TBL] [Abstract][Full Text] [Related]
56. The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin.
Priemel PA; Grohganz H; Gordon KC; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2012 Sep; 82(1):187-93. PubMed ID: 22683936
[TBL] [Abstract][Full Text] [Related]
57. Stability of indomethacin with relevance to the release from amorphous solid dispersions studied with ATR-FTIR spectroscopic imaging.
Ewing AV; Clarke GS; Kazarian SG
Eur J Pharm Sci; 2014 Aug; 60():64-71. PubMed ID: 24832964
[TBL] [Abstract][Full Text] [Related]
58. Dissolution Behavior of Flufenamic Acid in Heated Mixtures with Nanocellulose.
Mantas A; Mihranyan A
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168901
[TBL] [Abstract][Full Text] [Related]
59. A new protocol to determine the solubility of drugs into polymer matrixes.
Mahieu A; Willart JF; Dudognon E; Danède F; Descamps M
Mol Pharm; 2013 Feb; 10(2):560-6. PubMed ID: 23253068
[TBL] [Abstract][Full Text] [Related]
60. In vitro-in vivo correlation of the effect of supersaturation on the intestinal absorption of BCS Class 2 drugs.
Higashino H; Hasegawa T; Yamamoto M; Matsui R; Masaoka Y; Kataoka M; Sakuma S; Yamashita S
Mol Pharm; 2014 Mar; 11(3):746-54. PubMed ID: 24460473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
